Clinical trials: PIK3CA Mutation-Related Tumors

PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)

Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

• Not yet recruiting
• Age: All ages
• Phase 2

The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs.

Trial name

EPIK-RO (NCT07679269)

Testing

Alpelisib, Fulvestrant, Trastuzumab

Volunteers

51 people

Sponsor

Novartis Pharmaceuticals